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ABSTRACT
Purpose: To identify hypoxia-related biomarkers indicative of response and 
resistance to epirubicin treatment in patients with locally advanced breast cancer.
Patients and Methods: One hundred seventy-six women with T2-4 N0-1 breast 
tumours were randomly assigned to receive epirubicin 120 mg/m2/1-21 (EPI ARM), 
epirubicin 120 mg/m2/1-21 + erythropoietin 10.000 IU sc three times weekly (EPI-
EPO ARM) and epirubicin 40 mg/m2/w-q21 (EPI-W ARM). Sixteen tumour proteins 
involved in cell survival, hypoxia, angiogenesis and growth factor, were assessed by 
immunohistochemistry in pre-treatment samples. A multivariate generalized linear 
regression approach was applied using a penalized least-square minimization to 
perform variable selection and regularization.
Results: VEGF and GLUT-1 expression were significantly positively associated 
with complete response (CR) to treatment in all leave-one-out iterations. Bcl-2 
expression was inversely correlated with pCR, whilst EPO expression was positively 
correlated with pathological complete response (pCR). Haemaglobin and HIF-1a 
nuclear expression were inversely correlated with pCR. HB and HIF-1a expression 
were associated with a higher risk of relapse and overall survival.
Conclusion: Hypoxic biomarkers determines the epirubicin resistance in breast 
cancer. Assessment of such biomarkers, may be useful for predicting chemosensitivity 
and also anthracycline-based treatment outcome.
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INTRODUCTION
Current chemotherapy treatment practice applies 
therapy selection decisions empirically despite the 
observation that all regimens are not equally effective 
across patients. Thus specific predictors of response for 
this therapy are urgently required to select appropriate 
patients with breast cancer, provide clear directions for 
clinicians, and improve patients’ cancer journey [1].
It is recognised that anthracyclines reduce blood 
flow [2] leading to induction of tumour hypoxia-
related growth factors [3] such as vascular endothelial 
growth factor (VEGF), which paradoxically antagonise 
anthracylin’s therapeutic effect [4]. In this context, we 
previously showed that low haemoglobin (Hb) levels 
affect the efficacy of antineoplastic agents in patients 
with breast cancer, the corollary being a potential benefit 
of co-administration of erythropoietin to maintain 
oxygen delivery to the tumour bed [5], modulate 
tumour angiogenesis and thereby enhance the therapy 
effectiveness [6]. To test this effect. we initiated a 
randomised neoadjuvant clinical trial comparing two 
different schedules of neo-adjuvant epirubicin (EPI) single 
treatment, a “1-21 schedule” versus “weekly schedule” 
plus or minus the concomitant administration of EPO in 
patients with locally advanced breast cancer.
The aims of this study was 1) to assess whether the 
addition of EPO improves clinical or pathology response 
2) identify whether hypoxia-related biomarkers can 
identify resistance or response to EPI±EPI and 3) evaluate 
whether such biomarkers provides prognostic information 
for disease free or overall survival.
RESULTS
Clinical response to treatment
One hundred and seventy six patients were evaluated 
for disease response; three patients were not evaluated due 
to discontinuation of treatment. One hundred and sixty-
three of 176 patients (92.6%) showed a clinical response 
(CR or PR): 57/63 (90.5%) in the EPI 120 arm, 54/55 
(98.2%) in the EPI 120 + EPO arm and 52/58 (89.7%) in 
the EPI 40+EPO arm, respectively. Complete Response 
(CR) was obtained in 60 patients (34.1%), 16 (25.4%) in 
EPI 120 arm, 18 (32.7%) in EPI 120 + EPO arm and 26 
(44.8%) in EPI 40 + EPO arm, respectively. We compared 
responders with non-responders (NR) (i.e. PR plus CR, 
57 [90.5%] vs. SD plus Progression, 6 [9.5%] for the EPI 
120 group) with the aim of identifying markers involved 
in response to EPI. Furthermore, to determine markers 
associated with sensitivity to EPI, we compared the 
CR, 60 patients (34.1%) versus PR or NR, 116 patients 
[65.1%] (Supplementary Table 1).
Immunohistochemistry (Figure 1) is shown for 
most significant factors associated with response to neo-
adjuvant treatment including EPO; VEGF; GLUT-1 and 
HIF-1.
Factors associated with epirubicin sensitivity 
(CR)
The elastic-net reduced model for sensitivity 
showed that nuclear expression of VEGF was positively 
correlated with sensitivity to EPI in all leave-one-out 
iterations, and cytoplasmic expression of GLUT-1 was 
positively correlated with CR in 94 out of 108 (87%) 
iterations (Figure 2). GLUT-1 expression estimated 
coefficients showed slightly smaller values compared with 
those of VEGF expression. ER expression was inversely 
correlated with complete response (CR) in 71 of the 108 
fits (≈66%). None of these factors showed significant 
interaction with treatment in any of the leave-one-out 
iterations. All other variables were significant in less than 
40% of the leave-one-out iterations or not significant. 
The test of the model on the cases, which were left out 
from the model building (one at each iteration) gave an 
area under the ROC curve of 53% with a 95% confidence 
interval of 41% to 65%; thus the null hypothesis of area 
under the curve [7] equal to 50% (random prediction) 
could not be rejected.
Factors associated with response to epirubicin 
(non-responders vs responders)
PgR nuclear expression intensity and basal 
haemoglobin (Hb) level was the only significant 
prognostic factor in the reduced model of EPI resistance 
in all leave-one-out iterations. PgR consistently showed 
an inverse association with either partial or complete 
response, while Hb levels were positively correlated with 
treatment response (Figure 3). GLUT-1 expression was 
also positively associated with response to treatment in 
all leave-one-out iterations and p53 expression showed 
a significant positive correlation with clinical response 
in 103 of the 108 fits (≈95%). All other markers scores 
were significant in less than 50% of the leave-one-out 
iterations or not significant. Neither of these factors 
showed interaction with treatment in any of the leave-
one-out iterations. The test of the model on the cases 
which were left out from the model building (one per 
iteration) gave an area under the ROC curve of 60% with 
a 95% confidence interval of 41% to 81% so that the null 
hypothesis of AUC equal to 50% (random prediction) 
could not be rejected.
Factors associated with pathological complete 
response (pCR)
The reduced elastic net model for pathological 
complete response showed that bcl-2 expression inversely 
correlated with pathological complete response (≈99%), 
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whilst cytoplasmic EPO expression intensity showed direct 
correlation with pathological complete response in 98 out of 
99 (≈99%) leave-one-out iterations (Figure 4).
Hb basal levels and nuclear HIF-1α expression 
intensity were both inversely correlated with pCR in 56 of 
the 99 fits (≈57%). All the other variables were significant 
in <50% of the leave-one-out iterations or not significant. 
The test of the model on the cases, which were left out 
from the model building (one at each iteration) gave an 
area under the ROC curve of 58% with a 95% confidence 
interval of 41% to 75%; thus the null hypothesis of area 
under the curve [7] equal to 50% (random prediction) 
could not be rejected.
Factors associated with disease free survival 
(DFS) and overall survival (OS)
The reduced elastic net model for DFS showed 
that Hb basal level was associated with a higher risk of 
relapse in 97 of 108 (≈90%) leave-one-out iterations 
(Supplementary Figure 1). Additionally, nuclear HIF-1 
α expression also showed a positive correlation with a 
higher risk of relapse in 64 of 108 (≈59%) iterations.
The reduced elastic net model for OS showed that 
Hb basal level was associated with a higher risk of death 
in 98 of 108 (≈91%) leave-one-out iterations. HIF-1 α 
expression intensity was also correlated with the risk of 
death in 84 out of 108 (≈78%) iterations (Supplementary 
Figure 2). All other variables were significant in less than 
50% of the leave-one-out iterations or not significant.
DISCUSSION
The aim of neo-adjuvant therapy in breast cancer 
is to reduce the size of the primary tumour, thereby 
allowing for a conservative surgical approach [8]. Also, 
by allowing the possibility of “taking a second look”, 
Figure 1: Immunohistochemistry of most significant factors associated with response to neo-adjuvant treatment. (A) 
EPO; (B) VEGF; (C) GLUT-1; (D) HIF-1? omit.
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evaluating the pathological response to therapy “in vivo”, 
a neoadjuvant approach helps in the process of identifying 
the post-operative treatment strategies most suitable 
for a given patient and likely to succeed [9]. For these 
reasons, the neo-adjuvant approach represents the ideal 
scenario to allow treatment personalization on the basis 
of specific features of the tumour at diagnosis and after 
surgery. Several randomized studies have shown that 
anthracyclines, in association with taxanes, provide high 
rates of pCR in the neo-adjuvant setting [10, 11]; however, 
this therapeutic approach is ineffective in approximately 
half of the patients and associated with the risk of serious 
side effects [12]. The identification of reliable predictive 
factors would help clinicians with the selection of the 
most appropriate therapy for individual patients. In this 
context, it has been demonstrated that different breast 
cancer molecular sub-groups have differing pCR and 
survival rates. This is true in particular with regard to triple 
negative and HER-2-enriched breast cancer subgroups, 
whereas such a correlation is still controversial for the 
luminal subtypes [13]. Nevertheless, although HER-2 and 
topoisomerase II alpha (TOP2A) immunohistochemical 
expression have been proposed as markers of sensitivity 
to anthracyclines some studies suggest that these two 
Figure 2: Factors Associated With Epirubicin Sensitivity.
Oncotarget78874www.impactjournals.com/oncotarget
combined markers do not necessarily identify the only 
patients that will benefit from anthracyclines [14]. Thus, 
to date, no specific biomarkers have been identified that 
are able to predict tumour response to anthracycline-based 
chemotherapy.
Tumour hypoxia has been traditionally considered 
an obstacle to overcome in the treatment of solid 
tumours as it is associated with resistance to radiation 
and chemotherapy [15]. Our group previously showed 
that high expression of VEGF, GLUT-1, p53, markers of 
angiogenesis [16], tumour metabolism [17] and tumour 
proliferation [18, 19], and low expression of ER, are 
predictors of response to epirubicin. Among these, the 
role of GLUT-1 is still controversial, in fact it is unknown 
whether GLUT-1 is associated to hypoxia in breast cancer 
cells or it is a hypoxia-independent feature of transformed 
cells which display altered metabolism, as in other 
cancers [20]. Therefore, the discrepancy between the 
expression of hypoxia-markers and the rate of response to 
anthracyclines/DFS/OS that we found in this study could 
be explained by the fact that GLUT-1 is perhaps expressed 
in breast cells irrespective of the degree of hypoxia, or 
independently from it. A recent report demonstrated a 
requirement for GLUT-1 in mammary tumourigenesis 
Figure 3: Factors Associated With Epirubicin Response.
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[20, 21] as a consequence of the fact that early malignant 
transformation requires glucose. The metabolic alterations 
typically found in tumour cells, more than the response 
to hypoxia, could explain our results. Taken together 
our results may open the way to studies which could 
investigate inhibitors of GLUT-1 in combination with 
anthracyclines. It is well known that low expression of 
ER is related to an increased Ki67 index [22, 23], as 
well as amplification of HER-1/HER-2 signalling [24], 
increased tumour-angiogenesis [16] and metabolism 
[17]. Moreover high expression of p53, as detected by 
immunohistochemistry [25], is associated with inhibition 
of tumour apoptosis resulting in highly proliferative 
tumours, more likely to respond to chemotherapy [8, 
26]. On the other hand, we found that high expression 
of Pg receptors correlates with anthracycline treatment 
resistance. This fact could further strengthen the evidence 
of an existing relation between increased expression of 
steroid hormone receptors and aggressiveness of disease 
in breast cancer [27].
Further to this, we found that high HB levels and 
immunohistochemistry expression of bcl-2 and HIF-1α 
were inversely correlated with pCR. In 2012, Tanaka 
et al demonstrated that anthracycline chemotherapeutic 
Figure 4: Factors Associated With Pathological Complete Response.
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agents inhibit binding of the HIF-α/ARNT heterodimer to 
the target gene enhancer and reduce response to hypoxia 
[28]. Considering that GLUT-1 expression is controlled 
by HIF-1 and decreased oxidative phosphorylation [29], 
it may be that anthracyclines act by uncoupling the two 
mechanisms and that doxorubicin and daunorubicin 
act as potent inhibitors of HIF-1α -mediated gene 
transcription [30]. From our work, we can confirm 
the role of HIF-α expression as a marker of response 
during anthracycline-based chemotherapy and therefore 
hypothesize the possible use of anti-HIF-α in treatment 
of breast cancer.
Importantly, we found that EPO expression in 
the tumour context correlated with pCR. Hypoxia is 
associated with the induction of EPO and EPOR mRNA 
expression along with their related proteins in breast 
carcinomas [31]. EPO expression in turn stimulates 
tyrosine phosphorylation, DNA synthesis, migration of 
vascular endothelial cells, angiogenesis and proliferation 
in breast cancer cells [32, 33]. Furthermore, EPO also 
leads to increased expression of anti-apoptotic proteins 
such as bcl-2 and bcl-XL [34, 35] and their activation is 
likely to account, at least in part, for the enhanced anti-
tumour effect of anthracycline-based chemotherapy which 
accompanies a pCR.
Basal HB levels (≥ 13 gr/dl-1) expression was 
positively correlated with pCR as previously observed 
[5]. Haemoglobin blood concentration is responsible 
for the availability of oxygen within the tumour; high 
HB and therefore high oxygen delivery may cause 
the generation of hydrogen peroxide or nitric oxide, 
responsible of oxidative damage to tumour cells and 
induction of apoptosis [36]. However, oxygen distribution 
in the context of the tumour is heterogeneous, with the 
presence of very “low-oxygen” areas, predominantly 
because of severe structural abnormalities of the tumour 
microvessels, disturbed microcirculation, and tumour-
related anaemia [37].
In conclusion, predicting response to anthracycline-
based therapy is an ongoing challenge in breast cancer 
patients’ management. Immunohistochemistry expression 
of hypoxia-related markers could help identifying patients 
who will benefit from this type of chemotherapy. Co-
administration of hypoxia-targeting agents could provide 
further benefit. Moreover, routine haemoglobin levels 
testing during treatment, and correction of anaemia with 
concomitant administration of erythropoietin, could be 
of significant importance as it seems to directly affect 
patients’ outcome.
Finding biological markers of response to systemic 
and/or targeted therapies represents an inevitable step 
towards “personalised” medicine.
Table 1: Patients characteristics
Characteristic
EPI 120 EPI 120 + E EPI 40 + EP0
No. % No. % No. %
Median age, years 55 54 57
Range 29-70 33-68 32-70
TNM
 T2 56 86.2 44 80.0 52 88.1
 T3-4 9 13.8 11 20.0 7 11.9
 N0 43 66.2 36 65.5 41 69.5
 N1 22 33.8 19 34.5 18 30.5
Primary histology
 Ductal carcinoma 58 86.6 46 83.6 45 75.0
 Lobular carcinoma 6 9.0 6 10.9 12 20.0
 Ductal/lobular carcinoma 2 3.0 2 3.6 3 5.0
 Mucoid carcinoma 1 1.5 1 1.8 0 0.0
Grading
 2 16 25.0 22 40.0 13 21.7
 3 48 75.0 33 60.0 47 78.3
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MATERIALS AND METHODS
Patients and treatment evaluation
This was a single center, randomized, phase II trial 
which enrolled 198 patients with T2-4 N0-1 primary breast 
cancer, from January 2002 to November 2005. The trial 
was constituted of four treatment arms: Epirubicin 120 
mg/m2/1-21 (66 patients) (EPI ARM), Epirubicin ARM 
120 mg/m2/1-21 + erythropoietin (epoetin) alfa 10.000 
IU sc three times weekly (57 patients) (EPI-EPO ARM), 
Epirubicin 40 mg/m2/w-q21 (62 patients) (EPI-WARM) 
and Epirubicin 40 mg/m2/w-q21+ erythropoietin (epoetin) 
alfa 10.000 IU three times weekly (13 patients) (EPI-
EPO-W ARM). In the EPI-EPO arm erythropoietin was 
systematically administered when haemoglobin dropped 
below 12.0 g/dl during treatment. The authors originally 
planned to administer four cycles in all treatment arms but 
the EPI-EPO-W ARM was stopped early (and not included 
in the analysis) due to the high rate of patients’ refusal 
to self-administer erythropoietin (epoetin) alfa. Thus, the 
patients originally assigned to this arm were randomly 
reallocated to the other arms. In order to avoid bias, it 
was decided to exclude the 13 patients allocated in the 
EPI-EPO-W ARM from the analysis, therefore decreasing 
the sample size to 185 patients in total. In 9 patients, the 
response indicator was unavailable for technical reasons 
and thus these patients were also excluded from the 
Table 2: Biological markers considered in this study
IHC Molecular Markers Localization Median Mean 95% CI
Tissue microarray
 VEGF Intensity Cytoplasm 1.0 0.9 0.8 to 1.0
 HIF-1a Intensity Nucleus 0.0 0.5 0.4 to 0.6
 CA9 Intensity Membrane 0.0 0.4 0.3 to 0.6
 TP Intensity Cytoplasm 0.0 0.5 0.4 to 0.7
 TP Intensity Nucleus 1.0 1.1 0.9 to 1.3
 GLUT-1 Intensity Cytoplasm 1.0 1.2 1.0 to 1.4
 PHD2 Intensity Cytoplasm 1.0 1.2 1.0 to 1.4
 PHD2 Intensity Nucleus 0.0 0.5 0.4 to 0.6
 EPO Intensity Nucleus 2.0 2.0 1.9 to 2.2
 EPO Intensity Cytoplasm 2.0 2.1 2.0 to 2.3
 EPO-R Intensity Nucleus 3.0 2.2 2.1 to 2.4
 EPO-R Intensity Cytoplasm 3.0 2.8 2.7 to 2.9
 CD 31 LOW (79) MED (40) HIGH (45)
IHC Routine markers Median Mean 95% CI
 ER Nucleus 1.0 0.8 0.7 to 0.9
 PgR Nucleus 1.0 0.5 0.4 to 0.6
 Bcl2 Cytoplasm 1.0 0.8 0.7 to 0.9
 HER2 Membrane 0.0 0.2 0.1 to 0.2
 p53 Nucleus 1.0 0.6 0.5 to 0.6
Blood Routine Markers Median Mean 95% CI
 HB* Blood 13.6 13.6 13.4 to 13.7
 HCT* Blood 41.0 41.0 40.5 to 41.4
Note: Markers considered in the analysis had < 20% of missing values (ie the marker was assessed in at least or more than 
80% of the patients) or < 20% positivity in sample staining (ie, the marker stained positive in at least 20% of the samples).
Abbreviations: HIF-1 alpha, hypoxia-inducible factor 1 alpha; TP, tymidilato phosphorilasy;GLUT-1; PHD2; EPO; 
CA9; VEGF, vascular endothelial growth factor; ER, estrogen receptor; PgR, progesterone receptor. Haemoglobin (HB), 
Hematocritus (HCT).
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analysis. Hence, the final sample-size was composed of 
176 patients. Patients’ characteristics are shown in Table 1.
On first presentation, an incisional biopsy (0.5 to 
0.8 cm3) was performed. Tumour size and response was 
assessed by the same specialist, according to the WHO 
criteria [38] by the clinical measurement of the changes 
in the product of the two largest diameters recorded in 
two successive evaluations. Tumour progression (PD) 
was defined as an increase of at least 25% in tumour 
size; stable disease (SD) as an increase of less than 25%, 
or a reduction of less than 50%; partial response (PR) 
as a tumour shrinkage greater than 50%; and complete 
response (CR) as the complete disappearance of all 
clinical signs of disease. Pathologic complete response 
(pCR) was defined as the absence of neoplastic cells in 
the breast and in the axillary lymph nodes after histology. 
Surgery (quadrantectomy or modified radical mastectomy 
in association with full axillary node dissection) was 
planned after clinical reassessment. All patients subjected 
to quadrantectomy underwent irradiation of the residual 
breast (60 Gy delivered over 6 weeks). All patients 
received post operatively 6 cycles Cyclophosphamide, 
Methotrexate and 5-Fluorouracile (CMF regimen). 
Patients with positive oestrogen receptor primary tumour 
received tamoxifen (20 mg/daily), irrespective of the 
trail arm, starting after chemotherapy, up to progression 
or for a maximum of five years. All the recommended 
treatment modifications for hematologic toxicities used 
were previously described [39]. Toxicity was evaluated on 
the basis of National Cancer Institute Common Toxicity 
Criteria for Adverse Events, Version 3.0. The study 
was approved by the local ethics committee. Written 
informed consent was obtained from all patients before 
randomization.
Histopathologic grade and 
immunohistochemistry
Immunohistochemical evaluation for routine 
markers (bcl-2, p53, HER2, ER, PgR, and Ki67), as 
described elsewhere [5, 40], was performed on paraffin-
embedded tumour samples of whole tumour sections 
obtained at diagnosis. The antibodies, sources, and 
protocols used for the other markers are previously 
described [41]. Immunohistochemistry for all markers 
was performed on 5μ sections of tissue microarray 
containing two 1-mm diameter cores taken from selected 
morphologically representative tumour regions from the 
incisional biopsy (Table 2). Quality control was assessed 
on each block by haematoxylin and eosin staining. 
The Envision HRP kit (Dako; Cambridgeshire, United 
Kingdom) system was used for subsequent visualization. 
Staining was assessed in the nucleus for HIF1 α, Ki67, 
ER, PgR and p53, nucleus and cytoplasm for PHD1, 
PHD2, PHD3, TP, EPO, and EPO-R; membrane for 
CAIX, and HER2; cytoplasm for GLUT-1, Bcl-2 and 
VEGF. All sections had a negative control slide (no 
primary antibody) of an adjacent section to preclude 
nonspecific staining. Positive controls included breast 
carcinomas known to exhibit high levels of each marker. 
A tumour was considered positive if more than 10% of 
the surface area of the sample contained tumour cells. All 
immunohistochemically stained sections were assessed 
by light microscopy by two pathologists simultaneously 
at Nuffield Department of Clinical Laboratory Sciences, 
University of Oxford, UK. The observers were blinded 
to the patient’s clinical characteristics, patients’ outcome 
and samples’ origin. Intensity was semi-quantitatively 
assessed: 0 (no staining), 1 (weak staining), 2 (moderate 
staining), or 3 (strong staining) for nuclear HIF1-alpha, 
PHD1, PHD2, PHD3, CAIX, VEGF, TP, GLUT-1, 
EPO and EPO-R. The cut-off for PgR, ER, HER2, p53, 
bcl-2, Ki67 was as previously reported [41]. For the 
quantification of tumour angiogenesis CD31, a previously 
reported 25-point Chalkley eyepiece graticuleas 
[42], was used to count vascular spots identified by 
scanning the tumour at 40-100 by two observers over 
a conference microscope. Microvessels were defined 
as any immunoreactive endothelial cell (EC)s separate 
from adjacent microvessels. Vessels within the sclerotic 
body of the tumour were not included. Counting at x250 
magnification was then performed by rotating the graticule 
in the eyepiece to where the maximum number of dots 
overlay stained vessels. The mean of three counts was 
used in the subsequent analysis and tumours with counts 
>7 were considered high vascularity. Tumours with counts 
of less than 7 were considered as low (0-4) and median (5-
6) vascularity. Some of the markers scores were missing 
due to insufficient tumour or unsatisfactory staining. The 
approach to missing cases was to exclude cases where 
the value of the covariate under study was missing in the 
univariate analysis and to exclude cases when 1 or more 
covariates were missing in the multivariate analysis.
Statistical methodology
The methodology adopted for this study has been 
previously described in Generali et al. [41, 43]. Here, 
we provide a brief description for convenience. For data 
analysis we used a particular regression approach called 
elastic net (see Zou and Hastie [44]), which addresses 
the problem of variable selection and regularization in 
multivariate analyses by using least-square penalization. 
More specifically, the elastic net approach performs 
least-square minimization while enforcing a constraint 
on a combination of the sum of the absolute values of 
the regression coefficients and the sum of their squares. 
This constraint enables efficient variable selection and 
encourages a grouping effect, where strongly correlated 
predictors tend to stay in or out of the model together.
The markers introduced in the model are described 
in Table 2, and median, mean, and 95% quintiles are 
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provided. The categorization of the markers was based 
on the variables as described earlier. The clinical 
variables introduced in the model were tumour size (0 
if T ≤ 2, 1 if T > 2), nodal status (negative vs. positive), 
age, tumour grade, histological type, and treatment. All 
scores and clinical variables were standardized before 
being introduced in the model by applying location and 
scale transformation as suggested in Zou and Hastie [44].
The approach used to missing data was pairwise 
deletion (also known as available-case analysis) meaning 
that each analysis used all cases with no missing values 
for the variables involved in the analysis. This approach 
guarantees that the results are unbiased if the ‘missing 
completely at random assumption’ is satisfied [45], which 
can be considered as tenable in the study presented here. 
An alternative to the missing data approach adopted here 
is multiple imputation using chained equations [46]. 
Despite its popularity mainly due to the extreme flexibility 
it offers, this methodology still lacks a general theoretical 
justification, hence it was not considered for the analysis 
presented in this work.
Finally, an iterative leave-one-out approach was 
used to test the model. More specifically, at each iterations, 
one case (i.e. a single patient) was left out from the 
analysis, a fit of the model was produced for the remaining 
cases and a treatment response prediction was made for the 
left out case. This allowed testing of the models’ ability to 
predict treatment response, specificity and sensitivity, and 
respective area under the receiver operator characteristic 
curve, were estimated using these predictions.
All the analyses presented were performed using the 
R software (http://cran.r-project.org) using the packages 
elastic-net and glm-net.
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